98%
921
2 minutes
20
Ambient particulate matter (PM) and nitrogen dioxide (NO) are both major air pollutants with potential neurotoxic effects. Beyond fine PM (PM), large population-based evidence on the associations of coarse PM (PM) and NO, especially co-exposure to high-concentration PM and NO, with hospital admissions for Parkinson's disease (PD) is crucial for PD risk management. In this time-stratified case-crossover study, patients with a principal discharge diagnosis coded of PD (G20) were identified. The associations of PM, PM and NO with increased admissions for PD were investigated based on hospital admissions data from the urban basic medical insurance schemes across 233 cities at or above the prefecture level in China during 2013-2017. A total of 293,357 hospital admissions were included in the study. An interquartile range increase in PM (34.5 μg/m), PM (20.2 μg/m) and NO (19.5 μg/m) at lag 01was associated with increases of 1.80% (95% confidence interval [CI], 0.71-2.90%), 2.93% (95% CI, 1.44-4.45%) and 4.67% (95% CI, 2.90-6.47%) in PD admissions, respectively. Only associations for PM and NO remained statistically significant after controlling for the other air pollutants and generalized propensity score. In comparison with low-concentration exposure (<30 percentile concentration), high-concentration exposures (≥60 percentile concentration) to PM and NO were both positively associated with increased PD admissions. Meanwhile, co-exposures to moderate and heavy exceedance of PM and NO were respectively associated with an increase of 4.61% (95% CI, 2.58-6.68%) and 9.72% (95% CI, 5.75-13.85%) in PD admissions, compared with within-standard co-exposure. This innovative exploration provided new epidemiological evidence that PM and NO may increase the risk of PD admissions independent of the other air pollutants, and co-exposure is likely associated with a more pronounced increase in PD admissions than separate exposure.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.envpol.2025.127062 | DOI Listing |
J Ultrasound Med
September 2025
Evandro Chagas Infectious Diseases National Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Objectives: The risk of major venous thromboembolism (VTE) among patients with COVID-19 is high but varies with disease severity. Estimate the incidence of lower extremity deep venous thrombosis (DVT) in critically ill hospitalized patients with COVID-19, validate the Wells score for DVT diagnosis, and determine patients' prognosis.
Methods: This was an observational follow-up study in the context of the diagnosis and prognosis of DVT.
Eur J Case Rep Intern Med
September 2025
Department of Internal Medicine, Hospital Universitario San Agustín, Asturias, Spain.
Background: Although splenomegaly is a common finding in Epstein-Barr virus (EBV) infection, splenic infarction is rarely reported and may be under-recognised, especially in adults. Neurological complications such as aseptic meningitis are also uncommon but documented. The simultaneous occurrence of both complications in the context of primary EBV infection is exceptional.
View Article and Find Full Text PDFEur J Case Rep Intern Med
August 2025
Department of Internal Medicine, Dubai Hospital, Dubai Health, Dubai, Dubai, United Arab Emirates.
Introduction: Primary central nervous system vasculitis (primary CNS vasculitis) is a rare inflammatory disorder that affects small-to-medium-sized cerebral vessels, often leading to recurrent strokes. Diagnosis is vague due to non-specific neurological symptoms. Imaging findings, cerebrospinal fluid (CSF) analysis and exclusion of systemic vasculitis are essential for diagnosis.
View Article and Find Full Text PDFERJ Open Res
September 2025
Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background: In Belgium, age-standardised hospital admission and mortality rates for asthma and COPD are higher than the European average. Understanding the factors that lead to a hospitalised exacerbation and/or mortality is needed to optimise patient management.
Methods: Patients ≥18 years old obtaining two claims for drugs for obstructive airway diseases (ATC code R03) in 1 year between 2017 and 2022 were identified in Belgian nationwide claims-based data.
Front Oncol
August 2025
Health Management Department, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: Lung cancer remains a leading cause of cancer-related morbidity and mortality worldwide. As systemic therapy prolongs survival, improving patients' quality of life (QoL) has become a central goal of holistic care. Personalized nursing interventions, tailored to individual patient needs, have shown promise in oncology but lack large-scale evaluation in lung cancer populations.
View Article and Find Full Text PDF